Bionomics Limited Files 8-K for Material Definitive Agreement
Ticker: NEUP · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1191070
| Field | Detail |
|---|---|
| Company | Bionomics Limited/Fi (NEUP) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing, financials
TL;DR
BIONOMICS LTD (BNO) filed an 8-K on Oct 1 for a material definitive agreement. Watch for details.
AI Summary
On October 1, 2024, Bionomics Limited entered into a material definitive agreement. The company, incorporated in Australia, filed a Form 8-K with the SEC to report this event. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates a significant business development for Bionomics Limited, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, requiring careful evaluation of the terms and potential impact.
Key Numbers
- 001-41157 — SEC File Number (Identifies the specific SEC filing for Bionomics Limited.)
Key Players & Entities
- Bionomics Limited (company) — Registrant
- October 1, 2024 (date) — Date of earliest event reported
- Australia (location) — Jurisdiction of incorporation
- 200 Greenhill Road Eastwood, SA Australia 5063 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement?
The filing does not specify the details of the material definitive agreement, only that one was entered into on October 1, 2024.
What are the key financial statements included in the filing?
The filing indicates that financial statements and exhibits are included, but their specific content is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 1, 2024.
What is Bionomics Limited's principal executive office address?
Bionomics Limited's principal executive offices are located at 200 Greenhill Road Eastwood, SA Australia 5063.
What is the company's SIC code?
The Standard Industrial Classification (SIC) code for Bionomics Limited is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 594 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-10-01 18:01:06
Filing Documents
- ea0216237-8k_bionomic.htm (8-K) — 28KB
- ea021623701ex2-1_bionomic.htm (EX-2.1) — 359KB
- ea021623701ex99-1_bionomic.htm (EX-99.1) — 23KB
- ex2-1_001.jpg (GRAPHIC) — 5KB
- ex2-1_002.jpg (GRAPHIC) — 5KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001213900-24-084175.txt ( ) — 660KB
- bnox-20241001.xsd (EX-101.SCH) — 3KB
- bnox-20241001_lab.xml (EX-101.LAB) — 33KB
- bnox-20241001_pre.xml (EX-101.PRE) — 22KB
- ea0216237-8k_bionomic_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement On October 1, 2024, Bionomics Limited, an Australian corporation ("Bionomics"), and Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), entered into a Scheme Implementation Agreement to re-domicile from Australia to the U.S. state of Delaware pursuant to a Scheme of Arrangement under Australian law. Upon completion of the Scheme of Arrangement, Bionomics would become a wholly-owned subsidiary of Neuphoria. Under the Scheme of Arrangement: holders of ordinary shares in Bionomics will receive one share of common stock in Neuphoria for every 1,440 ordinary shares of Bionomics held as of record date; and holders of American Depositary Shares ("ADSs") of Bionomics will receive one share of common stock in Neuphoria for every 8 ADSs held in Bionomics as of the record date. The implementation of the Scheme of Arrangement is subject to customary conditions, including the approval of Bionomics shareholders and an Australian court as well as other regulatory approvals. Details of the terms and conditions are set out in the Scheme Implementation Agreement, which is attached as Exhibit 2.1 to this Form 8-K. Further information is included in the press release attached as Exhibit 99.1, which is incorporated by reference into this Item 1.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 2.1 Scheme Implementation Agreement, dated October 1, 2024, between Bionomics Limited and Neuphoria Therapeutics Inc. 99.1 Press Release, dated October 1, 2024, issued by Bionomics Limited. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIONOMICS LIMITED Date: October 1, 2024 By: /s/ Spyridon Papapetropoulos Spyridon Papapetropoulos President and Chief Executive Officer 2